Episodi

  • BENEFIT Trial: Redefining Frontline Multiple Myeloma Treatment for Transplant-Ineligible Patients

    BENEFIT Trial: Redefining Frontline Multiple Myeloma Treatment for Transplant-Ineligible Patients
    Jun 24 2026

    Weekly discussions on the latest evidence in hematologic oncology - from landmark trials to practice-changing papers.


    pulsosaudepodcast@gmail.com


    PAPER:

    • Isatuximab, lenalidomide, dexamethasone and bortezomib in transplant-ineligible multiple myeloma: the randomized phase 3 BENEFIT trial
    • Authors: Leleu X, Hulin C, Lambert J et al.
    • Journal: Nature medicine
    • https://doi.org/10.1038/s41591-024-03050-2
    Mostra di più Mostra meno
    27 min
  • SYMPATICO: Ibrutinib Plus Venetoclax in Relapsed Mantle Cell Lymphoma

    SYMPATICO: Ibrutinib Plus Venetoclax in Relapsed Mantle Cell Lymphoma
    Jun 17 2026

    Weekly discussions on the latest evidence in hematologic oncology - from landmark trials to practice-changing papers.


    pulsosaudepodcast@gmail.com


    PAPER:

    • Ibrutinib plus venetoclax in relapsed or refractory mantle cell lymphoma (SYMPATICO): a multicentre, randomised, double-blind, placebo-controlled, phase 3 study
    • Authors: Wang M, Jurczak W, Trneny M et al.
    • Journal: The Lancet. Oncology
    • https://doi.org/10.1016/S1470-2045(24)00682-X
    Mostra di più Mostra meno
    20 min
  • Conditioning Chemotherapy vs. Total Body Irradiation in Pediatric ALL: The FORUM Trial Reshapes Transplant Practice

    Conditioning Chemotherapy vs. Total Body Irradiation in Pediatric ALL: The FORUM Trial Reshapes Transplant Practice
    Jun 10 2026

    Weekly discussions on the latest evidence in hematologic oncology - from landmark trials to practice-changing papers.


    pulsosaudepodcast@gmail.com


    PAPER:

    • Total Body Irradiation or Chemotherapy Conditioning in Childhood ALL: A Multinational, Randomized, Noninferiority Phase III Study
    • Authors: Peters C, Dalle JH, Locatelli F et al.
    • Journal: Journal of clinical oncology : official journal of the American Society of Clinical Oncology
    • https://doi.org/10.1200/JCO.20.02529
    Mostra di più Mostra meno
    20 min
  • Acalabrutinib vs Ibrutinib in Relapsed CLL: The First Head-to-Head BTK Inhibitor Trial

    Acalabrutinib vs Ibrutinib in Relapsed CLL: The First Head-to-Head BTK Inhibitor Trial
    Jun 3 2026

    Weekly discussions on the latest evidence in hematologic oncology - from landmark trials to practice-changing papers.


    pulsosaudepodcast@gmail.com


    PAPER:

    • Acalabrutinib Versus Ibrutinib in Previously Treated Chronic Lymphocytic Leukemia: Results of the First Randomized Phase III Trial
    • Authors: Byrd JC, Hillmen P, Ghia P et al.
    • Journal: Journal of clinical oncology : official journal of the American Society of Clinical Oncology
    • https://doi.org/10.1200/JCO.21.01210
    Mostra di più Mostra meno
    25 min
  • The Interferon vs Hydroxyurea Question: Results from a Landmark Phase 3 Trial in MPNs

    The Interferon vs Hydroxyurea Question: Results from a Landmark Phase 3 Trial in MPNs
    May 27 2026

    Weekly discussions on the latest evidence in hematologic oncology - from landmark trials to practice-changing papers.

    pulsosaudepodcast@gmail.com


    PAPER:

    • A randomized phase 3 trial of interferon-α vs hydroxyurea in polycythemia vera and essential thrombocythemia
    • Authors: Mascarenhas J, Kosiorek HE, Prchal JT et al.
    • Journal: Blood
    • https://doi.org/10.1182/blood.2021012743
    Mostra di più Mostra meno
    27 min